Cyclosporine

Cyclosporine
Yikrazuul · Public domain · source
Name	Cyclosporine
Tradename	Neoral, Sandimmune, Restasis
Drug name	Cyclosporine
Routes of administration	Oral, intravenous, topical, ophthalmic
Bioavailability	Variable
Metabolism	Hepatic (CYP3A)
Elimination half-life	6–24 hours
CAS number	59865-13-3

Cyclosporine is an immunosuppressive peptide widely used to prevent organ transplant rejection and to treat selected autoimmune conditions. Originating from a fungal metabolite discovered in the 1970s, it revolutionized outcomes in Kidney transplant and Liver transplant medicine and influenced the careers of prominent clinicians and institutions. Its development and deployment intersect with major medical centers, biotechnology firms, regulatory agencies, and public health organizations.

Medical uses

Cyclosporine is a cornerstone in transplantation medicine, employed in maintenance immunosuppression after Kidney transplant, Liver transplant, Heart transplant, and some Bone marrow transplant protocols; it is often combined with agents developed at institutions such as National Institutes of Health, Mayo Clinic, Johns Hopkins Hospital, and companies like Novartis and Sandoz. Beyond transplantation, clinicians at centers including Massachusetts General Hospital and Cleveland Clinic use cyclosporine for steroid-refractory cases of Rheumatoid arthritis and for severe forms of Psoriasis and Atopic dermatitis in consultation with dermatology departments influenced by guidelines from societies like the American Academy of Dermatology and the European Academy of Dermatology and Venereology. Ophthalmic formulations are prescribed for chronic inflammatory eye diseases guided by research from institutions such as Bascom Palmer Eye Institute and Moorfields Eye Hospital. Selected autoimmune nephropathies treated in nephrology clinics at institutions like Mount Sinai Health System may also include cyclosporine under protocols aligned with recommendations from the American Society of Nephrology.

Pharmacology

Cyclosporine is a cyclic polypeptide that selectively inhibits intracellular signaling pathways in T lymphocytes by binding to cyclophilins characterized in structural studies from laboratories at Harvard Medical School and University of California, San Francisco. The cyclosporine–cyclophilin complex inhibits calcineurin, a mechanism elucidated in work associated with researchers linked to Max Planck Society and Karolinska Institutet, thereby reducing transcription factors that activate interleukin-2 genes described in immunology texts used at Oxford University and Cambridge University. Hepatic metabolism occurs primarily via CYP3A enzymes extensively characterized by pharmacologists at Food and Drug Administration and European Medicines Agency review panels; interactions with agents from Pfizer, Roche, and Gilead Sciences that induce or inhibit CYP3A are clinically significant. Pharmacokinetic variability noted in trials at Stanford University and Yale School of Medicine influences therapeutic drug monitoring strategies that evolved with input from World Health Organization and national guideline committees.

Adverse effects

Common adverse effects—including nephrotoxicity, hypertension, and neurotoxicity—were documented in multicenter studies involving centers such as Brigham and Women's Hospital and UCSF Medical Center and discussed at symposia sponsored by organizations like the American Society of Transplantation. Long-term complications such as chronic kidney disease and increased risk of infections and malignancies were subjects of cohort analyses published by groups at Imperial College London and Johns Hopkins Bloomberg School of Public Health; oncology collaborations with institutions like MD Anderson Cancer Center evaluated oncogenic risk. Drug–drug interactions leading to elevated cyclosporine levels with macrolide antibiotics from Abbott Laboratories or azole antifungals marketed by Merck prompted clinical alerts from regulators including Health Canada and European Medicines Agency. Patient monitoring protocols influenced by the National Kidney Foundation and transplant registries maintain surveillance for metabolic complications identified in studies at Mount Sinai.

Formulations and administration

Cyclosporine is available in oral capsule formulations originally commercialized by Sandoz and later refined by Novartis into microemulsion products, as well as intravenous preparations used in perioperative transplant care at tertiary centers like Cleveland Clinic. Ophthalmic emulsion formulations for chronic dry eye and inflammatory ocular disease were developed in collaboration with research groups at Bascom Palmer Eye Institute and approved following trials overseen by the Food and Drug Administration. Dosing regimens and therapeutic drug monitoring strategies were standardized in consensus statements involving the American Society of Transplantation, European Society for Organ Transplantation, and academic centers including Mayo Clinic.

History

The compound was isolated from a soil fungus in the 1970s by researchers at a pharmaceutical company later associated with Sandoz; early preclinical work occurred in collaboration with microbiologists from institutions like University of Basel and chemists connected to ETH Zurich. Clinical development accelerated in the late 1970s and early 1980s with pivotal trials conducted at transplant centers such as University Hospital of Zurich and University College Hospital, London, leading to rapid adoption in transplant programs influenced by surgeons at Massachusetts General Hospital and Stanford Hospital. The drug’s impact on survival and graft function shaped transplant policy discussions at meetings of the International Congress of the Transplantation Society and regulatory reviews by agencies like the Food and Drug Administration.

Regulatory status and availability

Cyclosporine received marketing authorization in multiple jurisdictions after evaluations by regulatory bodies including the Food and Drug Administration, European Medicines Agency, and Health Canada; national reimbursement decisions were influenced by cost-effectiveness assessments from agencies such as National Institute for Health and Care Excellence and health technology assessment units at universities like University of Toronto. Generic competition and biosimilar pathways involved manufacturers from India and China as well as multinational firms like Teva Pharmaceutical Industries, affecting availability across hospital formularies at institutions such as Johns Hopkins Hospital and clinics in low-resource settings supported by World Health Organization procurement programs.

Category:Immunosuppressants